James Battiste to Bevacizumab
This is a "connection" page, showing publications James Battiste has written about Bevacizumab.
Connection Strength
0.160
-
Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases. J Clin Neurosci. 2016 Apr; 26:161-3.
Score: 0.120
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
Score: 0.040